August Grants — October 2008
Abram, J., NIH, Universal Determinants of Alcohol–Induced Toxicity, $225,000; Altschuler, S., NIH, The Design Principles Underlying Cell Polarity in Yeast, $151,709; Boothman, D., NIH, Use of Beta-Iapachone for Lung Cancer Chemotherapy, $217,299; Bowers, D., NIH/St. Jude Children’s Research Hosp., Childhood Cancer Survivor Study, $65,449; Brekken, R., NIH, Matricellular Proteins as Regulators of Tumor Progression, $200,138.
Brugarolas, J., NIH, VEGF Regulation by the TSC2 Suppressor, $159,987; Castrillon, D., NIH, Mentoring and Research in Mouse Models of Cancer and Infertility, $111,354; Clegg, D., NIH, Regulation of Food Intake and Body Weight by Hypothalamic ERAlpha, $176,042; Clegg, D., NIH/Purdue Univ., Energy Dysregulation: Behavioral and Biological Signals, $9,313; Contreras, C., NIH, Genetic and Molecular Studies of Endometrial Cancer, $29,971; Cowan, C. NIH, Signaling Mechanisms of Retinal Axon Guidance, $220,500.
Crandall, C., NIH, Heat Stress and Circulatory Control, $293,617; Cullum, M., Telecognitive Assessment Extending Neuropsychology to Underserved Elders, $184,500; Dietschy, J., NIH, Control of Cholesterol Metabolism: Bile Acid Transport, $525,939; Falck, J., NIH, Novel Eicosanoids: Synthesis and Function, $85,237; Falck, J., NIH/Med. Coll. of Wisc., Lipid Modulators of Pulmonary Vascular Tone, $15,000.
Freeman, A., CDC, PS06-649, Packaging of Proven HIV Behavorial Interventions, $11,111; Gimi, B., NIH, Imaging Islets in Implantable Microcapsules, $269,188; Greene, R., NIH/McLean Hosp., Glutamatergic Dysfunction and Schizophrenia, $109,636; Henkemeyer, M., NIH, Bidirectional Tyrosine Kinase Signaling, $275,000; Hiesinger, R., NIH, Regulation of Synaptic Specificity in the Visual System by Intracellular Traffic, $250,000.
Huang, L., NIH, Erythropoietin Receptor Signaling in Erythropoiesis, $250,000; Igarashi, P., NIH, UT Southwestern O’Brien Kidney Research Core Center, $547,878; Isaacson, B., NIH/ Mass. Eye & Ear Infirmary, Sudden Hearing Loss Multicenter Treatment Trial, $6,369; Jain, M., NIH, Molecular Basis of Interferon Response in HCV, $115,000; Kedzierski, W., NIH, Elov14 in Retinal Physiology and Pathophysiology, $196,000.
Kodadek, T., NIH, Post-Translational Modification of Activators, $68,556; Kodadek, T., NIH, Novel Chemistry to Monitor and Manipulate the Immune System, $500,000; Kohler, J., NSF, CAREER: A Genetic Method to Study Interactions Among Extracellular Proteins, $106,369; Kohler, J., NSF, CAREER: A Genetic Method to Study Interactions Among Extracellular Proteins, $113,457; Levine, B., NIH, Aging Fitness & Failure: Mechanisms of Diastolic Dysfunction, $581,253.
Lister, G., NIH/Boston Univ., Event Recordings of High Risk Infants on Apnea Monitors, $24,472; Liu, Q., NIH, Regulatory Mechanisms of RNA Interference, $12,876; Liu, Y., NIH, Post-transcriptional Regulation of the Neurospora Circadian Clock, $210,000; Lu, Q.R., NIH, Olig2 in Oligodendrocyte Myelination and Remyelination, $219,267; Luo, X., NIH, Structure and Function of Spindle Checkpoint Proteins, $175,000.
Maalouf, N., NIH, Mentored Patient-Oriented Research Career Development Award, $107,840; Mammen, P., NIH, Regulation of Tissue Hemoglobins in the Heart, $100,000; Mangelsdorf, D., NIH, Role of FGF21 as a Hormonal Mediator of PPARalpha Actions, Project 4 of 10, $245,250; Mason, R., NIH/Tufts Univ., Fluorinated Cell Surfaces to Modulate Biological Function, $31,536; McKnight, S., NIH, NIH Director’s Pioneer Award, $488,250.
Mendelson, C., NIH, Cellular Mechanisms in the Induction of Aromatase, $204,428; Minna, J., U.S. Department of Defense/UT M.D. Anderson Cancer Center, Identification of Biomarkers of Response to Chemopreventive Agents in Lung Epithelium Using Genomic and Proteomic Techniques, $51,625; Mohan, C., NIH, Immunogenetics of Antibody Induced Nephritis, $220,000; Monteggia, L., NIH, Antidepressants and Intracellular Signaling Linked to BDNF, $188,656; Okada, P., NIH/Univ. of Pittsburgh, Pediatric Traumatic Brain Injury Consortium Hypothermia COOL KIDS Trial, $16,000.
Otwinowski, Z., NIH, The Crystallography of Macromolecules, $359,905; Papiez, L., NIH/Purdue Univ., Integrated Wireless Tracking and Dosimetry for Radiation Oncology, $43,089; Parada, L., NIH, NF Center: From Animal Models to Therapeutics, $1,075,818; Pertsemlidis, A., NIH, microRNA Regulation of Drug Sensitivity in Non-Small-Cell Lung Cancer, $171,000; Ramilo, O., HRSA, Ryan White Title IV Program, $1,236,628; Ramilo, O., HRSA, Ryan White Care Act Title IV Adolescent Initiative, $325,001.
Ramos, H., NIH, Species-Specific IFN-a/b-Dependent Th1 Development, $29,163; Raskin, P., NIH/Case Western Reserve Univ., Epidemiology of Diabetes Interventions and Complications-Clinical Coordinating Center; 151,980; Ready, J., NIH, Catalytic Synthesis of Alpha-Branched Carbonyl Compounds, $159,294; Repa, J., NIH, Nuclear Hormone Receptor Regulation of Cholesterol Absorption, $200,000; Russell, D., NIH, Mouse Phenotype Core, Project 9 of 10, $50,000.
Sanchez, P., NIH/Duke Univ., Multiple Dose Pharmacokinetic Study of Meropenem in Young Infants (<91 Days) With Suspected or Complicated Intra-Abdominal Infections, $38,635; Scaglioni, P., NIH, Post-Transcriptional Regulation of PML Function, $123,975; Scheuermann, R., NIH/Northrop Grumman Info. Tech., Bioinformatics Resource Centers for Biodefense and Emerging/Re-Emerging Infectious Diseases, $114,739; Schiller, J., NIH/Eastern Co-op. Oncology Group, ECOG Thoracic Committee, $6,105; Skinner, C., NIH, Facilitating Risk-Appropriate Colorectal Cancer Testing, $353,924.
Swienton, R., DHHS/Texas A&M Univ., Bioterrorism Training and Curriculum Development Program, $203,703; Taurog, J., NIH, HLA-B27 and Experimental Spondyloarthropathy, $264,110; Thomas, G., NIH/Univ. of Missouri, Dual AAV Vectors for Duchenne Muscular Dystrophy Therapy, $22,000; Trivedi, M., NIH, Combining Medications to Enhance Depression Outcomes, $230,285; Trivedi, M., NIH, Using Information Technology to Provide Measurement Based Care for Chronic Illness, $293,066.
Unger, R., NIH, The Glucoregulatory and Liporegulatory Peptide Hormones, $180,800; van Oers, N., NIH, T Cell Receptor Signaling by Phosphorylated Forms of TCR, $186,033; Victor, R., NIH, Barber-Based Intervention for Hypertension in Black Men, $476,546; Ward, E.S., NIH, Structure-Function Studies of Human FcRn, $232,541; Ward, E.S., NIH, Mechanistic Studies of FcRn Inhibitors for the Treatment of IgG-Mediated Diseases, $220,000.
Whitehurst, A., NIH, Harnessing Functional Genomics to Reveal Cancer Specific Determinants of Mitosis, $87,413; Wiebe, D., NIH, Parental Involvement in Diabetes Care Across Adolescence, $417,970; Wiebe, D., NIH, Parental Involvement in Diabetes Care Across Adolescence, $489,028; Williams, K., NIH, Genetic Dissection of the Central GLP-1 System, $49,646; Winkler, W., NIH, Regulation of Magnesium Homeostasis in Bacillus Subtilis, $152,000.
Womack, K., NIH, Radiological Biomarkers for Frontotemporal Lobar Degeneration, $106,360; Wright, W., NIH, Gene Expression in Aging and Development, $251,577; Wuelfing, C., NIH, The Role of Cdc42 and Rac in NK Cell Activation, $122,625; Zhao, D., U.S. Army, Multimodal Imaging of Pathophysiological Changes and Their Role in Development of Breast Cancer Brain Metastasis, $100,000; Zhang, C., NIH, Expansion of Hematopoietic Stem Cells by Angiopoietin-Like 2, $152,000; Zigman, J., NIH, Identification of Central Targets of Ghrelin, $116,072.
Altschuler, S., Welch Fndtn., Multidimensional Profiling of Chemical Perturbations to the Insulin-Signaling Pathway, $50,000; Amatruda, J., ACS, A Model of EWS-FLI1 Cellular Function and Ewing’s Sarcoma in Zebrafish, $44,000 (Leacock, S., fellow); Auchus, R., Welch Fndtn., Hydrogen Atom Transfer Mechanisms in Steroid Hydroxylases, $50,000; Bezprozvanny, I., Welch Fndtn., Structural Studies of Huntington Protein, $50,000.
Bezprozvanny, I., Alzheimer’s Drug Discovery Fndtn. and Inst. for the Study of Aging, Ryanodine Receptor Type 1 as Target for AD: Evaluation of Dantrolene and Tetracaine, $122,000; Blount, P., Welch Fndtn., Determining Lipid-Protein Interactions for a Channel Gated by Membrane Tension, $50,000; Bobulescu, A., Amer. Soc. of Nephrology, Regulation of the Renal Sodium/Proton Exchanger NHE3 by Dopamine: Role of Protein Phosphatase 2A, $90,000; Brown, K., Welch Fndtn., Design and Synthesis of Tumor-Targeted Drug Delivery Systems for Lung Cancer Therapy, $50,000.
Brugarolas, J., Fundacion Caja Madrid, Study of the Molecular Mechanism of Regulation of mTORCI by Means of the Induced Protein Even Hypoxia REDDI, $41,000 (Vega-Rubin de Celis, S., fellow); Bruick, R., Welch Fndtn., Cellular Iron Sensing and Regulation of Iron Regulatory Protein 2, $50,000; Bucholz, R., Orthopaedic Research Edu. Fndtn., Journal of Bone and Joint Surgery Resident Journal Club Program, $2,000 (Eisner, E., fellow); Chen, C., Welch Fndtn., Synthesis of Massadine Core Skeleton: Development of a General Approach to Efficient Synthesis of Natural Oroidin Dimers, $50,000.
Chen, Z., Welch Fndtn., Biochemical Mechanism of IKK Activation by TRAF Proteins, $80,000; Chook, Y., Welch Fndtn., The Structural and Biochemical Mechanisms of Pho4 Nuclear Import and Export, $50,000; Chuang, D., Welch Fndtn., Mitochondrial Signaling by Reversible Phosphorylation, $60,000; Claassen, C., Amer. Fndtn. for Suicide Prevention, Does the Nature of Treatment Provided After a Suicide Attempt Impact the Risk of Repetition?, $31,875.
Cobb, M., Welch Fndtn., Regulatory and Catalytic Properties of MAP Kinase Cascades, $90,000; Corey, D., Welch Fndtn., Recognition of Chromosomal DNA by Synthetic Oligomers, $90,000; De Brabander, J., Welch Fndtn., Synthetic Studies Toward Spirastrellolide, $70,000; Debose-Boyd, R., Jane Coffin Childs Mem. Fund for Med. Research, Mechanism of HMG-CoA Reductase mRNA Translational Regulation, $44,500 (Lee, S.H., fellow).
Deisenhofer, J., Welch Fndtn., Structural Studies of Cryptochromes and Their Effectors, $90,000; DeMartino, G., Welch Fndtn., Deubiquitylation by the 26S Proteasome, $50,000; Gardner, K., Welch Fndtn., Comparative Studies of the Signaling Mechanisms of Flavin-Based Protein Photosensors, $50,000; Garrard, W., Welch Fndtn., Formaldehyde Cross-Linking for Assay of DNA Looping Between Transcriptional Enhancers as an Inverse Function of 5-Methylcytosine Content, $50,000.
Gilles-Gonzalez, M., Welch Fndtn., Enzymology of the DosT Oxygen Sensor or M tuberculosis, $50,000; Goldsmith, E., Welch Fndtn., Serpin Inhibitory Mechanism, $80,000; Grishin, N., Welch Fndtn., Structural Studies of Novel NMV Synthetase Encoded by nadE, $50,000; Hammes, S., Welch Fndtn., Steroidogenesis in the Mouse Ovary, $50,000.
Hiesinger, R., Welch Fndtn., Biochemical Characterization of a Synaptic Function of Palmitoleic Acid, the Product of a Novel Δ9 Fatty Acid Desaturase, $50,000; Hoffman, S., Welch Fndtn., Novel Palmitoyl Protein Thioesterases, $50,000; Hooper, L., Welch Fndtn., Biochemical Basis for Peptidoglycan Binding by a Bactericidal Lectin, $50,000; Hsieh, J., Welch Fndtn., Chemical Regulation of Neural Progenitor/Cancer Stem Cells, $50,000.
Jiang, J., Welch Fndtn., Biochemical Characterization of Modular Ubiquitin Ligases Involved in Signal Transduction, $50,000; Jiang, Y., Welch Fndtn., Structural and Functional Studies of RCK-Regulated Potassium Channel, $50,000; Kliewer, S., Welch Fndtn., Regulation of Lipid Metabolism and Insulin Sensitivity by Nuclear Fatty Acid Receptors and Fibroblast Growth Factor 21, $50,000.
Kodadek, T., Welch Fndtn., Discovery of Small-Molecule Substitutes for Therapeutic Antibodies, $80,000; Krämer, H., Welch Fndtn., Protein Lipid Interactions in Endocytosis, $50,000; Kumar, K., Arthritis Fndtn., How SLAM Breaches B-Cell Tolerance, $50,000; Lehrman, M., Welch Fndtn., Endoplasmic Reticulum Stress-Dependent Hexose Phosphate Mobilization, $60,000.
Li, W., Welch Fndtn., Small Molecules as Modulators of Cell-Cell Junctional Communication, $50,000; Liu, Q., Welch Fndtn., Mechanistic Studies of the Drosophila RNA Interference Pathway, $50,000; Liu, Y., Arthritis Fndtn., Impact of CXCR4 and IFI 202 on Lupus Pathogenesis, $50,000; Liu, Y., Welch Fndtn., Biochemical Analysis of COP9 Signalosome: A Conserved Cullin Deneddylation Enzyme, $50,000.
Lum, L., Welch Fndtn., Modulation of Canonical Wnt Pathway Activity Using Small Molecules, $80,000; Lynch, K., Welch Fndtn., Structural Characterization of a Novel Transition in Spliceosome Assembly, $50,000; Mangelsodorf, D., Welch Fndtn., Ligand Binding Properties of Nematode Orphan Nuclear Receptors, $80,000; Norgard, M., Welch Fndtn., Crystallographic Analysis of Treponema pallidum Lipoproteins, $50,000.
Orth, K., Welch Fndtn., Biochemical Characterization of Yeast Pbs2 Kinase Mutants That Suppress the Inhibitory Activity of Yersinia Effector YopJ, $50,000; Phillips, M., Welch Fndtn., Mechanistic Analysis of the Function of a-Difluoromethylornithine in Trypanosoma brucei, $90,000; Prestige, C., Cystic Fibrosis Fndtn., Cystic Fibrosis Care and Teaching Center, $130,280; Ranganathan, R., Welch Fndtn., Evolutionary Design of Protein Structure and Function, $60,000.
Ready, J., Welch Fndtn., Asymmetric Synthesis of Nigellamine A5, $50,000; Rizo-Rey, J., Welch Fndtn., NMR Methods to Study Membrane Proteins in Lipid Bilayers, $60,000; Robertson, D., Welch Fndtn., The Role of the Post Lens Tear Film in Lipid Raft-Mediated Pseudomonas Internalization, $25,000; Robertson, D., Welch Fndtn., Career Development Award, $50,000.
Rosen, M., Welch Fndtn., Genetically Encoded Photoswitchable Proteins: Tools to Understand Cell Migration and Signaling, $50,000; Ross, E., Welch Fndtn., Phospholipase C-b as Gg GAP and Effector, $50,000; Russell, D., Welch Fndtn., Mammalian Etherase Enzymes, $60,000; Solberg, T., Amer. Soc. for Therapeutic Radiology and Oncology, Astro Radiation Oncology Physics Residency Training Program 2008, $12,000.
Sternweis, P., Welch Fndtn., Structure and Mechanism of Signaling Enzymes and Pathways, $50,000; Süel, G., Welch Fndtn., Amplification of Stochastic Fluctuations in Biochemical Reactions as a Mechanism for Cellular Differentiation, $50,000; Thomas, P., Welch Fndtn., Mechanistic Studies of an ATP-Dependent Chloride Channel, $60,000; Wang, X., Welch Fndtn., Delineating the Biochemical Pathway Underlining Autophagic Cell Death, $80,000.
White, M., Welch Fndtn., Analysis of the Functional Significance of Complex Protein/Protein Interactions, $80,000; Winkler, W., Welch Fndtn., Affinity-Based Purification of Riboswitch Ligands, $50,000; Wu, L., Welch Fndtn., Using Multiple Chemical Fluorophors to Profile the Spatial and Temporal Organization of the Insulin Response Network, $50,000; Yanagisawa, H., Welch Fndtn., Novel Mechanisms of Matrix Metalloprotease Regulation by Fibulin-5, $50,000.
Yu, G., Welch Fndtn., Chemical Mechanism of the g-Secretase Complex, $50,000; Yin, H., Welch Fndtn., Regulation of Phosphatidylinositol 5-Kinase g by Tyrosine Phosphorylation, $50,000; Yu, H., Welch Fndtn., Structural Analysis of the Mad2-Dependent Spindle Checkpoint Signaling, $50,000; Zeltser, I., Championship Hearts Fndtn., Early Cardiovascular Screening Pilot, $125,600.
Zhao, Y., Welch Fndtn., A Novel Method for Probing Protein Geranylgeranylation, $50,000; Zou, H., Welch Fndtn., A Novel Tubulin Acetylation Catalyzed by San Acetyltransferase, $50,000.
Pharmaceutical studies, dollar amounts not available
Arko, F., Evaluation of EndoRefix Endovascular Delivery System and Staple; Clagett, G., A Randomized Double-Blind, Placebo-Controlled Parallel-Group Study of the Efficacy and Safety of Four Administrations of XRP00038/NV1FGF 4mg at Two-Week Intervals on Amputation or any Death in Critical-Limb Ischemia Patients With Skin Lesions; Fielder, J., A Randomized, Double Blind, Double Dummy, Parallel Group, Active Controlled Trial to Evaluate the Antiviral Efficacy of 400 mg QD neVirapine Extended Release Formulation in Comparison to 200 mg BID neVirapinE Immediate Release in Combination With Truvada in Antiretroviral Therapy Naive HIV-1 Infected Patients.
Girod, C., An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis Who Complete the CAPACITY Studies; Kenkel, J., Clinical Efficacy Evaluation of Lumenis Short Pulse Fractional CO2 Ablative Devices; Lee, W., A Phase 3 Study of Two-Dose Regimens of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C; Lemack, G., A Single-Masked, Randomized, Multicenter, Two-Arm Parallel Study Comparing the Safety and Effectiveness of Bulkamid and Contigen as Bulking Agents for the Treatment of Stress Urinary Incontinence in Females.
Lotan, Y., Prospective Validation of Bladder Cancer Detection Nomogram; McGuire, D., A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed; Oden, J., Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes; Pandya, A., A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Imiquimod Creams in the Treatment of External Genital Warts.
Raskin, P., A 26-Week, Open-Label, Randomized, Active Comparator Study of Generex Oral-lyn Spray and Injected Human Insulin in Subjects With Type-1 Diabetes Mellitus; Raskin, P., A Phase 3, Multicenter, Open-Label, Randomized, Clinical Trial Evaluating the Efficacy and Safety of Technosphere Insulin Inhalation Powder in Combination With Lantus vs. Humalog in Combination With Lantus in Subjects With Type 1 Diabetes Mellitus Over a 16-Week Treatment Period; Raskin, P., Randomized Subcutaneous Insulin in Inpatients Trial: Aggressive vs. Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin; Roehrborn, C., Cetrorelix Pamoate (AEZS-102) in Patients With Symptomatic BPH: An Open-Labeled Safety and Efficacy Assessment Study.
Toto, R., A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of Safety, Pharmacokinetics and Pharmacodynamics of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy on Background ACEi and/or ARB Therapy; Trivedi, M., A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose Titration, Add-On Study of TC-52142 – 8 mg in the Treatment of Major Depressive Disorder With Subjects Who Are Partial Responders or Non-Responders to Citalopram Therapy; Truelson, J., A Pilot Study of AuroLase Therapy in Patients With Refractory and/or Recurrent Tumors of the Head and Neck; Zellers, T., Coarctation of the Aorta Stent Trial; Zellers, T., Gore Helex Septal Occluder Post-Approval Study.